"Data Determines the Success or Failure of the Biohealth Industry"
Korea's Single-Payer Health Insurance System Enables Vast Data Accumulation

Approve Data Use Only for Research That Meets the "Public-Interest Criteria"
Ease Regulations Such

"Now that artificial intelligence (AI) has emerged as a game changer in the biohealth industry, we must strategically leverage this infrastructure and foster the biohealth industry as a new growth engine for the Korean economy."


On February 9, Sung Won, Head of the Micro Institutional Research Team at the Economic Research Institute of the Bank of Korea, stressed this point in the report titled "BOK Issue Note - Strategies to Foster the Advanced Biohealth Industry, Focusing on Building a Bio Data Utilization Infrastructure (Sung Won, Choi Iseul, and Lee Dongwon)." Sung stated, "AlphaFold, the AI that won the 2024 Nobel Prize in Chemistry, learned from massive datasets and predicted hundreds of millions of protein structures in a short period of time. This is a representative case that suggests that, in the era of AI innovation, high-quality, large-scale data is a powerful competitive asset that determines the success or failure of the biohealth industry," adding, "We must utilize Korea's infrastructure for collecting and linking bio data."


Why The Bank Of Korea Says AI Is A Biohealth Game Changer... And Why It Proposes A National Authorization-Based Open Data System View original image
AI as a game changer in the biohealth industry... Korea's single-payer health insurance system enables vast data accumulation

Amid the risk of low growth, the biohealth industry (pharmaceuticals and medical devices) is drawing attention as a new growth engine. Due to rising medical demand from population aging and the accelerating convergence of biotechnology and AI, the global biohealth market is projected to grow at an average annual rate of 5.0% over the next five years. This is roughly twice the growth rate of automobiles, one of Korea's key industries, which stands at 2.7%. In particular, AI shortens new drug development timelines by 30% to 50%, significantly reducing research and development (R&D) costs and creating new markets such as precision medicine and surgical-assistance robots, thereby giving follower countries like Korea an opportunity to overtake leading nations.


Korea holds health insurance and hospital clinical data on 50 million people, collected under its single national health insurance system. Sung noted, "This can become a national strategic asset of extremely high scarcity worldwide, to the extent that it is called the 'diamond of the AI era,'" and added, "If we build large-scale, high-quality bio data based on our data collection and linkage infrastructure and use it strategically, Korea can establish itself not only as a joint development partner for global leading companies, but also as a global biohealth R&D hub that leads multinational clinical trials."


Why The Bank Of Korea Says AI Is A Biohealth Game Changer... And Why It Proposes A National Authorization-Based Open Data System View original image

However, current utilization of bio data remains low. Sung analyzed, "This is because there is an 'incentive mismatch' in which the risks and costs of data use are borne by the data subjects (individuals) and data holders (hospitals), while the benefits are dispersed across the users (companies and researchers) and society at large."


Why The Bank Of Korea Says AI Is A Biohealth Game Changer... And Why It Proposes A National Authorization-Based Open Data System View original image
Incentives must be redesigned... A national authorization-based open bio data system is needed

To resolve this structural problem and activate data utilization, Sung proposed a "national authorization-based open bio data system." Under this system, data use would be approved only for research that has passed prior review and meets the public-interest criteria defined by law, while for approved research, regulations would be eased, for example by exempting prior consent requirements and supporting data distribution, with the goal of mitigating the incentive mismatch.


The idea is to guarantee public-interest use as defined by law through prior review and authorization, and to grant data subjects control rights that allow them to refuse or re-authorize data use at any time, thereby encouraging voluntary data provision based on trust. Sung said, "Empirical analysis shows that such policies of 'guaranteeing public-interest use' and 'strengthening information control rights' increase the willingness to provide general physical information and mental health information by 8.2 percentage points and 15.5 percentage points, respectively."


For uses that are recognized as serving the public interest through review, there is a need to reduce researchers' legal and administrative burdens by easing regulations, such as exempting prior consent and allowing broad consent. Sung added, "By establishing an integrated brokerage hub that provides end-to-end support from data exploration and combination to review and provision, and by fostering data brokers to vitalize the data distribution ecosystem, we should lower data access costs while providing a reasonable compensation framework for the production and sharing of high-quality data by private hospitals and others."


To ensure the effectiveness of the "national authorization system," Sung argued that Korea should consider establishing a separate dedicated body, similar to that of the European Union (EU), with independence, expertise, and financial sustainability. He emphasized, "Rather than directly managing data, this dedicated body should focus on its role as a market enabler that supports the private data ecosystem and as a guarantor of trust."



He expressed expectations that the national authorization system would turn bio data into a strategic asset and provide a new growth engine for the Korean economy in a low-growth phase. Sung said, "By expanding the data market and improving R&D efficiency, this will create a virtuous cycle that propels Korea into a global biohealth R&D hub and generates quality jobs," adding, "By promoting data utilization across all areas from personalized health management and new drug development to policy making, it will ultimately make a substantial contribution to improving public health."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing